MedPath

Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital

Not Applicable
Conditions
type2 diabetes
Registration Number
JPRN-UMIN000028153
Lead Sponsor
Tokyo Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
42
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease) 2) Females who are pregnant or who intend to become pregnant within the study 3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV 4) Contraindication with dapagliflozin 5) Patient who disqualified from the study by the investigator for any reason other than given above.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath